Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, they pose the risk of immune-related adverse events, including ICI-mediated acute kidney injury (ICI-AKI). Recent studies have implicated proton pump inhibitors (PPIs) as potential contributors to ICI-AKI development. This meta-analysis examines the association between PPI use and ICI-AKI, exploring a potential modifiable risk factor in ICI therapy while also reviewing the possible outcomes of ICI-AKI. Methods: We conducted a comprehensive systematic review and meta-analysis of observational studies, assessing the risk of ICI-AKI in cancer patients concurrently using PPIs and potential outcomes. Odds ratios (ORs) were pooled using random-effects models. Subgroup analyses and sensitivity analyses were performed to evaluate heterogeneity and potential biases. Results: A total of 14 studies involving 12,694 patients were included. In total, we analyzed 639 patients with all-cause AKI and 779 patients with ICI-AKI. The pooled OR for the overall incidence of AKI from all-causes was 1.57 (95% confidence interval [CI] 1.02–2.40) among patients on PPIs. Specifically, the risk of ICI-AKI associated with PPI use was significantly higher, with a pooled OR of 1.84 (95% CI 1.16–2.90). This indicates approximately 84% higher likelihood of developing ICI-AKI with concurrent use of PPIs. Additionally, among patients with ICI-AKI, 67% had complete or partial recovery of renal function, 32% progressed to chronic kidney disease (CKD), and about 36% died during a follow-up period of at least 3 months. Conclusion: This meta-analysis highlights the importance of cautious PPI prescription in cancer patients undergoing ICI therapy. Clinicians are advised to evaluate the risks and benefits of PPI use and consider alternative therapies when feasible.

1.
Seethapathy
H
,
Zhao
S
,
Chute
DF
,
Zubiri
L
,
Oppong
Y
,
Strohbehn
I
, et al
.
The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors
.
Clin J Am Soc Nephrol
.
2019
;
14
(
12
):
1692
700
.
2.
Cortazar
FB
,
Kibbelaar
ZA
,
Glezerman
IG
,
Abudayyeh
A
,
Mamlouk
O
,
Motwani
SS
, et al
.
Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study
.
J Am Soc Nephrol
.
2020
;
31
(
2
):
435
46
.
3.
Miao
J
,
Herrmann
SM
.
Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis
.
Clin Kidney J
.
2023
;
16
(
11
):
1834
44
.
4.
Gupta
S
,
Short
SAP
,
Sise
ME
,
Prosek
JM
,
Madhavan
SM
,
Soler
MJ
, et al
.
Acute kidney injury in patients treated with immune checkpoint inhibitors
.
J Immunother Cancer
.
2021
;
9
(
10
):
e003467
. Erratum in: J Immunother Cancer. 2023 Apr;11(4).
5.
Isik
B
,
Alexander
MP
,
Manohar
S
,
Vaughan
L
,
Kottschade
L
,
Markovic
S
, et al
.
Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events
.
Kidney Int Rep
.
2021
;
6
(
4
):
1022
31
.
6.
Page
MJ
,
McKenzie
JE
,
Bossuyt
PM
,
Boutron
I
,
Hoffmann
TC
,
Mulrow
CD
, et al
.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
.
BMJ
.
2021
;
372
:
n71
.
7.
DerSimonian
R
,
Laird
N
.
Meta-analysis in clinical trials
.
Control Clin Trials
.
1986
;
7
(
3
):
177
88
.
8.
Khwaja
A
.
KDIGO clinical practice guidelines for acute kidney injury
.
Nephron Clin Pract
.
2012
;
120
(
4
):
c179
84
.
9.
Meraz-Muñoz
A
,
Amir
E
,
Ng
P
,
Avila-Casado
C
,
Ragobar
C
,
Chan
C
, et al
.
Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes
.
J Immunother Cancer
.
2020
;
8
(
1
):
e000467
.
10.
Stein
C
,
Burtey
S
,
Mancini
J
,
Pelletier
M
,
Sallée
M
,
Brunet
P
, et al
.
Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort
.
Nephrol Dial Transplant
.
2021
;
36
(
9
):
1664
74
.
11.
Abdelrahim
M
,
Mamlouk
O
,
Lin
H
,
Lin
J
,
Page
V
,
Abdel-Wahab
N
, et al
.
Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
.
OncoImmunology
.
2021
;
10
:
1927313
. .
12.
Espi
M
,
Teuma
C
,
Novel-Catin
E
,
Maillet
D
,
Souquet
PJ
,
Dalle
S
, et al
.
Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study
.
Eur J Cancer
.
2021
;
147
:
29
39
.
13.
Gérard
AO
,
Andreani
M
,
Fresse
A
,
Parassol
N
,
Muzzone
M
,
Pinel
S
, et al
.
Immune checkpoint inhibitors-induced nephropathy: a French national survey
.
Cancer Immunol Immunother
.
2021
;
70
(
11
):
3357
64
.
14.
Koks
MS
,
Ocak
G
,
Suelmann
BBM
,
Hulsbergen-Veelken
CAR
,
Haitjema
S
,
Vianen
ME
, et al
.
Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study
.
PLoS One
.
2021
;
16
(
6
):
e0252978
.
15.
Oleas
D
,
Bolufer
M
,
Agraz
I
,
Felip
E
,
Muñoz
E
,
Gabaldón
A
, et al
.
Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience
.
Clin Kidney J
.
2021
;
14
(
5
):
1364
70
.
16.
Shimamura
Y
,
Watanabe
S
,
Maeda
T
,
Abe
K
,
Ogawa
Y
,
Takizawa
H
.
Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study
.
Clin Exp Nephrol
.
2021
;
25
(
5
):
479
87
.
17.
Baker
ML
,
Yamamoto
Y
,
Perazella
MA
,
Dizman
N
,
Shirali
AC
,
Hafez
N
, et al
.
Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
.
J Immunother Cancer
.
2022
;
10
(
3
):
e004421
.
18.
Ji
MS
,
Wu
R
,
Feng
Z
,
Wang
YD
,
Wang
Y
,
Zhang
L
, et al
.
Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study
.
Sci Rep
.
2022
;
12
(
1
):
18752
.
19.
Manohar
S
,
Ghamrawi
R
,
Chengappa
M
,
Goksu
BNB
,
Kottschade
L
,
Finnes
H
, et al
.
Acute interstitial nephritis and checkpoint inhibitor therapy: single center experience of management and drug rechallenge
.
Kidney360
.
2020
;
1
(
1
):
16
24
.
20.
Manohar
S
,
Kompotiatis
P
,
Thongprayoon
C
,
Cheungpasitporn
W
,
Herrmann
J
,
Herrmann
SM
.
Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis
.
Nephrol Dial Transplant
.
2019
;
34
(
1
):
108
17
.
21.
Yan
H
,
Tang
M
,
Zhu
W
,
Yang
Y
.
Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors
.
Clin Exp Nephrol
.
2023
;
27
(
7
):
603
12
.
22.
Chen
J-J
,
Lee
T-H
,
Kuo
G
,
Yen
CL
,
Lee
CC
,
Chang
CH
, et al
.
All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality
.
Clin Kidney J
.
2024
;
17
(
1
):
sfad292
.
23.
Izzedine
H
,
Mateus
C
,
Boutros
C
,
Robert
C
,
Rouvier
P
,
Amoura
Z
, et al
.
Renal effects of immune checkpoint inhibitors
.
Nephrol Dial Transplant
.
2017
;
32
(
6
):
936
42
.
24.
Miao
J
,
Sise
ME
,
Herrmann
SM
.
Immune checkpoint inhibitor related nephrotoxicity: advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge
.
Front Nephrol
.
2022
;
2
:
1017921
.
25.
Marco
T
,
Anna
P
,
Annalisa
T
,
Francesco
M
,
Stefania
SL
,
Stella
D
, et al
.
The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
.
Ther Adv Med Oncol
.
2019
;
11
:
1758835919875549
.
26.
Neumann
K
,
Ostmann
A
,
Breda
PC
,
Ochel
A
,
Tacke
F
,
Paust
HJ
, et al
.
The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis
.
Sci Rep
.
2019
;
9
(
1
):
2038
.
27.
Farooqui
N
,
Zaidi
M
,
Vaughan
L
,
McKee
TD
,
Ahsan
E
,
Pavelko
KD
, et al
.
Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors
.
Kidney Int Rep
.
2023
;
8
(
3
):
628
41
.
28.
Izzedine
H
,
Gueutin
V
,
Gharbi
C
,
Mateus
C
,
Robert
C
,
Routier
E
, et al
.
Kidney injuries related to ipilimumab
.
Invest New Drugs
.
2014
;
32
(
4
):
769
73
.
29.
Herrmann
SM
,
Perazella
MA
.
Immune checkpoint inhibitors and immune-related adverse renal events
.
Kidney Int Rep
.
2020
;
5
(
8
):
1139
48
.
30.
Lohia
S
,
Vlahou
A
,
Zoidakis
J
.
Microbiome in chronic kidney disease (CKD): an omics perspective
.
Toxins
.
2022
;
14
(
3
):
176
.
31.
Hobby
GP
,
Karaduta
O
,
Dusio
GF
,
Singh
M
,
Zybailov
BL
,
Arthur
JM
.
Chronic kidney disease and the gut microbiome
.
Am J Physiol Renal Physiol
.
2019
;
316
(
6
):
F1211
7
.
32.
Xu
LY
,
Zhao
HY
,
Yu
XJ
,
Wang
JW
,
Zheng
XZ
,
Jiang
L
, et al
.
Clinicopathological features of kidney injury related to immune checkpoint inhibitors: a systematic review
.
J Clin Med
.
2023
;
12
(
4
):
1349
.
33.
Fernandez-Juarez
G
,
Perez
JV
,
Caravaca-Fontán
F
,
Quintana
L
,
Shabaka
A
,
Rodriguez
E
, et al
.
Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis
.
Clin J Am Soc Nephrol
.
2018
;
13
(
12
):
1851
8
.
34.
Kanbay
M
,
Copur
S
,
Siriopol
D
,
Yildiz
AB
,
Berkkan
M
,
Popa
R
, et al
.
The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
.
Clin Kidney J
.
2023
;
16
(
5
):
817
26
.
35.
Chen
B
,
Yang
C
,
Dragomir
MP
,
Chi
D
,
Chen
W
,
Horst
D
, et al
.
Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
.
Ther Adv Med Oncol
.
2022
;
14
:
17588359221111703
.
You do not currently have access to this content.